Potassium Citrate
Grundinformationen
- CAS
6100-05-6- Standard-SMILES
O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+]- InChIKey
PJAHUDTUZRZBKM-UHFFFAOYSA-K- Summenformel
- C6.H7.K3.O8
- Durchschnittliche Molmasse
- 324,41 g/mol
- Monoisotopische Masse
- 323,9052116
Überblick
Potassium citrate monohydrate is a hydrate that is the monohydrate form of potassium citrate. It has a role as a diuretic. It contains a potassium citrate (anhydrous).
Namen und Bezeichner
- Bevorzugter Name
- Potassium Citrate
- IUPAC
- tripotassium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate
- Englischer Name
- Potassium citrate monohydrate
- Summenformel
- C6H11KO8
- Molmasse
- 250.24
Namen und Synonyme
Potassium citrate monohydrateKalii citrasUROCIT-KK-cit-vEffercitrateCymaclearINS NO.332(II)Potassium-citKali CitricumEE90ONI6FFPot citINS-332(II)
Weitere Namen anzeigen
TRIPOTASSIUM CITRATE MONOHYDRATEHydroxycitric acid (tripotassium hydrate)Potassium citrate hydrateCITRIC ACID TRIPOTASSIUM SALT MONOHYDRATEKH2PO49tri-Potassium citrateTrikaliumcitratH2O,BPPotassium Citrate FCC
E-332(II)NSC-760107CHEBI:64746Pot cit effUrocit-k 5meqCitrate, PotassiumRefChem:6154DTXSID0041222
Datenbank-Bezeichner
- CAS
6100-05-6、866-84-2- PubChem CID
- 2735208
- DTXSID
DTXSID8042501
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 142 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 17
- Formalladung
- 0
- Komplexität
- 211
Experimentelle und physikochemische Eigenschaften
Chemical ClassesMetals -> Organic Acids, Metal Salts
CosmeticsCosmetic ingredients (Potassium Citrate) -> CIR (Cosmetic Ingredient Review)
Food AdditivesEMULSIFIER OR EMULSIFIER SALT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT, NUTRIENT SUPPLEMENT, PH CONTROL AGENT, SEQUESTRANT -> FDA Substance added to food
Density1.98 @25 °C
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Animal DrugsFDA approved animal drugs -> Active ingredient
Food Contact SubstancesFCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR
Physical DescriptionWhite odorless solid; [Merck Index] White powder or granules; [Alfa Aesar MSDS]
Physikochemische Eigenschaften
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 100% (181 of 181) of all reports.
Not Classified
Aggregated GHS information provided per 181 reports by companies from 2 notifications to the ECHA C&L Inventory.
Not Classified
Gefahrenhinweise
Regulatory Information
Chemical: 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate
Tripotassium citrate monohydrate: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, tripotassium salt, monohydrate: Human health tier I assessment
Hazards SummaryMay cause irritation; [Alfa Aesar MSDS] See Tripotassium citrate.
EPA Safer ChemicalChemical: Potassium citrate, monohydrate
Hazard Classes and Categories
Not Classified
Not Classified
Sicherheit und Schutzausrüstung
Protective Action Criteria (PAC)
2.1 [mg/m3]
23 [mg/m3]
140 [mg/m3]
2.2 [mg/m3]
24 [mg/m3]
150 [mg/m3]
Toxikologische Informationen
Chemie und Industrie
Pharmakologische Informationen
ATC Code
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Pharmacodynamics
Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.
Mechanism of Action
After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
Metabolism/MetabolitesPotassium Citrate is absorbed and the citrate is metabolised to bicarbonate.
FDA Pharmacological Classification
KALI CITRICUM
Acidifying Activity [MoA]; Anti-coagulant [EPC]; Calcium Chelating Activity [MoA]; Calculi Dissolution Agent [EPC]; Decreased Coagulation Factor Activity [PE]
POTASSIUM CITRATE
Calcium Chelating Activity [MoA]; Calculi Dissolution Agent [EPC]; Decreased Coagulation Factor Activity [PE]; Acidifying Activity [MoA]; Anti-coagulant [EPC]
MeSH Pharmacological Classification
Agents that promote the excretion of urine through their effects on kidney function.
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Zugehörige Reaktionen
3
Notizen zur Verbindung
Wird geladen…